Is Zilbrysq Associated with Cancer Risks?
There is no evidence or information provided that suggests Zilbrysq is associated with an increased likelihood of cancer.
What is Zilbrysq?
Zilbrysq is a medication used to treat relapsing forms of multiple sclerosis (MS) in adults [1]. Multiple sclerosis is a chronic disease that affects the central nervous system [2].
How Does Zilbrysq Work?
Zilbrysq is a sphingosine 1-phosphate (S1P) receptor modulator [1]. It works by preventing certain types of white blood cells (lymphocytes) from entering the brain and spinal cord, which are parts of the central nervous system [1][3]. By reducing the number of these lymphocytes in the central nervous system, Zilbrysq helps to decrease inflammation and nerve damage associated with MS [3].
What are the Known Side Effects of Zilbrysq?
Common side effects of Zilbrysq can include upper respiratory infections, high blood pressure, and liver enzyme elevation [1]. More serious potential side effects, as with other S1P receptor modulators, could include infections, bradycardia (slow heart rate), and macular edema (swelling in the eye) [4]. Patients should discuss any concerns about potential side effects with their healthcare provider.
What Other Treatments are Available for Relapsing MS?
Other treatments for relapsing forms of multiple sclerosis include other S1P receptor modulators, disease-modifying therapies that work through different mechanisms such as interferon beta, glatiramer acetate, and infused therapies like natalizumab and ocrelizumab [5]. The choice of treatment depends on individual patient factors, disease activity, and physician recommendation [5].
Sources
1. https://www.drugs.com/zilbrysq.html
2. https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20351396
3. https://www.rxlist.com/zilbrysq-drug.htm
4. https://www.pfizer.com/products/product-detail/zilbrysq
5. https://www.nationalmssociety.org/Treating-MS/Medications